Claire Gourzones
Overview
Explore the profile of Claire Gourzones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saegerman C, Diep A, Renault V, Donneau A, Stamatakis L, Coppieters W, et al.
Commun Med (Lond)
. 2022 May;
2:1.
PMID: 35603280
Background: Nursing home (NH) residents have been severely affected during the COVID-19 pandemic because of their age and underlying comorbidities. Infection and outbreaks in NHs are most likely triggered by...
2.
Herviou L, Ovejero S, Izard F, Karmous-Gadacha O, Gourzones C, Bellanger C, et al.
Clin Epigenetics
. 2021 Sep;
13(1):174.
PMID: 34530900
Background: Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable. The search for new therapeutic targets is therefore essential. In addition to a wide panel of...
3.
Saegerman C, Donneau A, Speybroeck N, Diep A, Williams A, Stamatakis L, et al.
Transbound Emerg Dis
. 2021 Aug;
69(4):e194-e203.
PMID: 34357691
Nursing home (NH) residents and staff have been severely affected by the COVID-19 pandemic. The aim of this study was to examine the use of weekly saliva RT-qPCR testing for...
4.
Gourzones C, Bret C, Moreaux J
Front Genet
. 2019 Oct;
10:861.
PMID: 31620167
Multiple myeloma (MM) is a malignancy characterized by accumulation of malignant plasma cells within the bone marrow (BM). MM is considered mostly without definitive treatment because of the inability of...
5.
de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, et al.
Haematologica
. 2019 Jul;
105(3):784-795.
PMID: 31289205
Multiple myeloma (MM) account for approximately 10% of hematological malignancies and is the second most common hematological disorder. Kinases inhibitors are widely used and their efficiency for the treatment of...
6.
Gourzones C, Bellanger C, Lamure S, Gadacha O, de Paco E, Vincent L, et al.
Cancers (Basel)
. 2019 Mar;
11(4).
PMID: 30925767
Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development...
7.
Gourzones C, Ferrand F, Amiel C, Verillaud B, Barat A, Guerin M, et al.
Virol J
. 2013 Apr;
10:119.
PMID: 23590857
Background: Because latent Epstein Barr (EBV)-infection is a specific characteristic of malignant nasopharyngeal carcinoma (NPC), various molecules of viral origin are obvious candidate biomarkers in this disease. In a previous...
8.
Gourzones C, Jimenez A, Busson P
Cancer
. 2012 Feb;
118(18):4634.
PMID: 22298292
No abstract available.
9.
Gourzones C, Barjon C, Busson P
Semin Cancer Biol
. 2012 Jan;
22(2):127-36.
PMID: 22249142
Like other human solid tumors, nasopharyngeal carcinoma (NPC) is a tissue and a systemic disease as much as a cell disease. Tumor cell population in NPC is highly heterogeneous. Heavy...
10.
Jimenez A, Gressette M, Barjon C, Wei M, Gourzones C, Busson P
BMC Biotechnol
. 2011 Mar;
11:26.
PMID: 21435248
Background: Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation, especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells combined...